Literature DB >> 2153351

Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases.

U Specks1, W J Martin, M S Rohrbach.   

Abstract

In this study we evaluated the disease specificity of bronchoalveolar lavage fluid angiotensin-converting enzyme (BALF-ACE), its correlation with cellular constituents of bronchoalveolar lavage fluid (BALF), and for sarcoidosis, with other proposed markers of disease activity. Furthermore, the question of the clinical value of BALF-ACE determinations in in interstitial lung diseases or any of its subgroups was addressed. The study population consisted of 222 patients, 69 with biopsy proven sarcoidosis, 3 with hypersensitivity pneumonitis, 4 with acute histoplasmosis, 27 with idiopathic pulmonary fibrosis (IPF), 4 with rheumatoid arthritis-related interstitial fibrosis, 9 with pulmonary drug toxicity, 16 with pulmonary malignancies, 26 with other parenchymal lung disease entities, and 30 in whom the final diagnosis remained indeterminate. Elevated BALF-ACE concentrations were seen in all diagnostic categories. In sarcoidosis BALF-ACE levels correlated well with lavage lymphocyte counts (r = 0.49; p less than 0.0001), in contrast to IPF where they correlated well with lavage neutrophil counts (r = 0.51; p less than 0.007). The correlation of BALF-ACE and serum-ACE was significant. In sarcoidosis the mean BALF-ACE level was lower for patients with Stage-I chest roentgenographic patterns (0.664 U/L), compared to those with Stage II (1.112 U/L) and Stage III (1.083 U/L). It was concluded that elevated BALF-ACE levels are not specific for sarcoidosis. The correlations of BALF-ACE levels with different cellular constituents of BALF suggest a different cellular origin of BALF-ACE. In sarcoidosis BALF-ACE levels correlate well with other proposed markers of disease activity and seem to reflect pulmonary activity better than serum ACE.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153351     DOI: 10.1164/ajrccm/141.1.117

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  17 in total

1.  An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein.

Authors:  Abdolkarim Sheikhi; Mohammad Hojjat-Farsangi
Journal:  Hum Vaccin Immunother       Date:  2020-07-14       Impact factor: 3.452

2.  Dynamic Variation of RAS on Silicotic Fibrosis Pathogenesis in Rats.

Authors:  Bo-Nan Zhang; Xin Zhang; Hong Xu; Xue-Min Gao; Gui-Zhen Zhang; Hui Zhang; Fang Yang
Journal:  Curr Med Sci       Date:  2019-07-25

3.  Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis.

Authors:  M Molina-Molina; A Serrano-Mollar; O Bulbena; L Fernandez-Zabalegui; D Closa; A Marin-Arguedas; A Torrego; J Mullol; C Picado; A Xaubet
Journal:  Thorax       Date:  2006-04-06       Impact factor: 9.139

Review 4.  Modeling radiation-induced lung injury: lessons learned from whole thorax irradiation.

Authors:  Tyler A Beach; Angela M Groves; Jacqueline P Williams; Jacob N Finkelstein
Journal:  Int J Radiat Biol       Date:  2018-10-25       Impact factor: 2.694

5.  Angiotensinogen gene G-6A polymorphism influences idiopathic pulmonary fibrosis disease progression.

Authors:  M Molina-Molina; A Xaubet; X Li; A Abdul-Hafez; K Friderici; K Jernigan; W Fu; Q Ding; J Pereda; A Serrano-Mollar; A Casanova; E Rodríguez-Becerra; F Morell; J Ancochea; C Picado; B D Uhal
Journal:  Eur Respir J       Date:  2008-05-28       Impact factor: 16.671

6.  Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist.

Authors:  M Otsuka; H Takahashi; M Shiratori; H Chiba; S Abe
Journal:  Thorax       Date:  2004-01       Impact factor: 9.139

7.  The Angiotensin Converting Enzyme Insertion/Deletion polymorphism is not associated with an increased risk of death or bronchopulmonary dysplasia in ventilated very low birth weight infants.

Authors:  Krishna Yanamandra; John Loggins; R John Baier
Journal:  BMC Pediatr       Date:  2004-12-20       Impact factor: 2.125

8.  Imbalance of pro- and anti-inflammatory cytokines in pulmonary sarcoidosis.

Authors:  J Müller-Quernheim
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

9.  Gene expression profiling reveals novel TGFbeta targets in adult lung fibroblasts.

Authors:  Elisabetta A Renzoni; David J Abraham; Sarah Howat; Xu Shi-Wen; Piersante Sestini; George Bou-Gharios; Athol U Wells; Srihari Veeraraghavan; Andrew G Nicholson; Christopher P Denton; Andrew Leask; Jeremy D Pearson; Carol M Black; Kenneth I Welsh; Roland M du Bois
Journal:  Respir Res       Date:  2004-11-30

10.  Chronic Activation of the Renin-Angiotensin System Induces Lung Fibrosis.

Authors:  Jiaolong Wang; Li Chen; Bohao Chen; Angelo Meliton; Shu Q Liu; Yongyan Shi; Tianjing Liu; Dilip K Deb; Julian Solway; Yan Chun Li
Journal:  Sci Rep       Date:  2015-10-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.